{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ribavirin+%2B+Pegylated+interferon-alpha&page=2", "query": { "intervention": "Ribavirin + Pegylated interferon-alpha", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 38, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ribavirin+%2B+Pegylated+interferon-alpha&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ribavirin+%2B+Pegylated+interferon-alpha&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T05:48:05.128Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01330316", "title": "A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BI 201335", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 119, "start_date": "2011-07", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-06-30", "last_synced_at": "2026-10-03T05:48:05.128Z", "location_count": 20, "location_summary": "Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01330316" }, { "nct_id": "NCT00984620", "title": "Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BI 201335", "type": "DRUG" }, { "name": "Pegylated Interferon-alpha (IFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 160, "start_date": "2009-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2015-09-07", "last_synced_at": "2026-10-03T05:48:05.128Z", "location_count": 6, "location_summary": "Tulepo, Mississippi • New York, New York • Germantown, Tennessee + 3 more", "locations": [ { "city": "Tulepo", "state": "Mississippi" }, { "city": "New York", "state": "New York" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Jackson", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00984620" }, { "nct_id": "NCT02452814", "title": "Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HCV" ], "interventions": [], "intervention_types": [], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 8, "start_date": "2014-05-07", "completion_date": "2017-05-03", "has_results": false, "last_update_posted_date": "2018-02-06", "last_synced_at": "2026-10-03T05:48:05.128Z", "location_count": 2, "location_summary": "Dallas, Texas • Houston, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02452814" }, { "nct_id": "NCT01405027", "title": "Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Hepatitis C", "Genotype 1" ], "interventions": [ { "name": "Educational Intervention", "type": "PROCEDURE" }, { "name": "Patient education and management skills training", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Chronic Liver Disease Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2011-12", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-01-06", "last_synced_at": "2026-10-03T05:48:05.128Z", "location_count": 43, "location_summary": "Beverly Hills, California • Calabasas, California • Santa Monica, California + 34 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Calabasas", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01405027" }, { "nct_id": "NCT01399619", "title": "Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "BI201335", "type": "DRUG" }, { "name": "BI201335 24W", "type": "DRUG" }, { "name": "Bi 201335", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 310, "start_date": "2011-09", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-08-29", "last_synced_at": "2026-10-03T05:48:05.128Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Palm Springs, California • San Francisco, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01399619" }, { "nct_id": "NCT01358864", "title": "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "BI 201335", "type": "DRUG" }, { "name": "Pegylated Interferon-alpha (IFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 678, "start_date": "2011-06", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-08-29", "last_synced_at": "2026-10-03T05:48:05.128Z", "location_count": 18, "location_summary": "North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01358864" }, { "nct_id": "NCT00774397", "title": "Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "BI 201335 NA 240 mg QD / LI", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "BI 201335 NA 120mg QD / LI", "type": "DRUG" }, { "name": "BI 201335 NA 240 mg QD", "type": "DRUG" }, { "name": "BI 201335 NA 240 mg BID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 719, "start_date": "2008-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2015-11-16", "last_synced_at": "2026-10-03T05:48:05.128Z", "location_count": 10, "location_summary": "San Francisco, California • Chicago, Illinois • Lutherville, Maryland + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00774397" }, { "nct_id": "NCT00627926", "title": "A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Pegylated Interferon Alfa 2a", "type": "BIOLOGICAL" }, { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1095, "start_date": "2008-03", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2014-08-08", "last_synced_at": "2026-10-03T05:48:05.128Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00627926" }, { "nct_id": "NCT00991289", "title": "Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection", "Hepatitis C Infection" ], "interventions": [ { "name": "Nitazoxanide (NTZ)", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a (PEG)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2010-01", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-03T05:48:05.128Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00991289" }, { "nct_id": "NCT01297270", "title": "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BI201335", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 658, "start_date": "2011-04", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-09-18", "last_synced_at": "2026-10-03T05:48:05.128Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01297270" } ] }